Technical Analysis for PRAX - Praxis Precision Medicines, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 15.51 | -1.90% | -0.30 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| Historical PRAX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | -1.90% | |
| Lower Bollinger Band Walk | Weakness | -1.90% | |
| Lower Bollinger Band Touch | Weakness | -1.90% | |
| Oversold Stochastic | Weakness | -1.90% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 2 % | about 4 hours ago |
| Lower Bollinger Band Support | about 4 hours ago |
| Possible Inside Day | about 5 hours ago |
| Possible NR7 | about 5 hours ago |
| 60 Minute Opening Range Breakdown | about 7 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 03/17/2021
Praxis Precision Medicines, Inc. Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement Purdue Neuroscience Company; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Neuroscience Nervous System Disorders Central Nervous System Disorders Epilepsy Precision Medicine Major Depressive Disorder Depression Depressive Disorder Oligonucleotide Huntington's Disease Neuron Spinal Muscular Atrophy Treatment Of Major Depressive Disorder Antisense RNA Essential Tremor Receptor Positive Ionis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 60.95 |
| 52 Week Low | 15.37 |
| Average Volume | 340,536 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 19.07 |
| 20-Day Moving Average | 17.79 |
| 10-Day Moving Average | 16.78 |
| Average True Range | 1.22 |
| ADX | 22.91 |
| +DI | 14.47 |
| -DI | 25.15 |
| Chandelier Exit (Long, 3 ATRs) | 16.77 |
| Chandelier Exit (Short, 3 ATRs) | 19.02 |
| Upper Bollinger Bands | 20.46 |
| Lower Bollinger Band | 15.12 |
| Percent B (%b) | 0.07 |
| BandWidth | 30.02 |
| MACD Line | -1.14 |
| MACD Signal Line | -0.98 |
| MACD Histogram | -0.1655 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 16.59 | ||||
| Resistance 3 (R3) | 16.69 | 16.44 | 16.41 | ||
| Resistance 2 (R2) | 16.44 | 16.16 | 16.39 | 16.35 | |
| Resistance 1 (R1) | 15.97 | 15.99 | 15.85 | 15.87 | 16.29 |
| Pivot Point | 15.72 | 15.72 | 15.65 | 15.67 | 15.72 |
| Support 1 (S1) | 15.25 | 15.44 | 15.13 | 15.15 | 14.73 |
| Support 2 (S2) | 15.00 | 15.27 | 14.95 | 14.67 | |
| Support 3 (S3) | 14.53 | 15.00 | 14.61 | ||
| Support 4 (S4) | 14.43 |
